Literature DB >> 9130946

HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group.

I Theodorou, L Meyer, M Magierowska, C Katlama, C Rouzioux.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9130946

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  58 in total

Review 1.  Pharmacogenetics and the future of medical practice.

Authors:  Klaus Lindpaintner
Journal:  J Mol Med (Berl)       Date:  2003-03-25       Impact factor: 4.599

2.  Evaluating plague and smallpox as historical selective pressures for the CCR5-Delta 32 HIV-resistance allele.

Authors:  Alison P Galvani; Montgomery Slatkin
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-25       Impact factor: 11.205

3.  Pharmacogenetics and the future of medical practice.

Authors:  Klaus Lindpaintner
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

4.  R5 human immunodeficiency virus type 1 (HIV-1) replicates more efficiently in primary CD4+ T-cell cultures than X4 HIV-1.

Authors:  Becky Schweighardt; Ann-Marie Roy; Duncan A Meiklejohn; Edward J Grace; Walter J Moretto; Jonas J Heymann; Douglas F Nixon
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

5.  Usage of the coreceptors CCR-5, CCR-3, and CXCR-4 by primary and cell line-adapted human immunodeficiency virus type 2.

Authors:  N Sol; F Ferchal; J Braun; O Pleskoff; C Tréboute; I Ansart; M Alizon
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

6.  CCR5Delta32 59537-G/A promoter polymorphism is associated with low translational efficiency and the loss of CCR5Delta32 protective effects.

Authors:  Qingwen Jin; Lokesh Agrawal; L Meyer; R Tubiana; Ioannis Theodorou; Ghalib Alkhatib
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

7.  Counterpoint: Cord blood stem cell therapy for acquired immune deficiency syndrome.

Authors:  Ghalib Alkhatib
Journal:  Stem Cells Dev       Date:  2009 Jan-Feb       Impact factor: 3.272

8.  Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32.

Authors:  N L Michael; J A Nelson; V N KewalRamani; G Chang; S J O'Brien; J R Mascola; B Volsky; M Louder; G C White; D R Littman; R Swanstrom; T R O'Brien
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  CXCR4 and CCR5 genetic polymorphisms in long-term nonprogressive human immunodeficiency virus infection: lack of association with mutations other than CCR5-Delta32.

Authors:  O J Cohen; S Paolucci; S M Bende; M Daucher; H Moriuchi; M Moriuchi; C Cicala; R T Davey; B Baird; A S Fauci
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

Review 10.  HIV: cell binding and entry.

Authors:  Craig B Wilen; John C Tilton; Robert W Doms
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.